Cargando…

Health State Utilities for Adverse Events Associated with Chimeric Antigen Receptor T-Cell Therapy in Large B-Cell Lymphoma

BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy provides effective treatment for large B-cell lymphoma (LBCL). Cost-utility analyses examining and comparing the value of these treatments require health state utilities representing key characteristics to differentiate among therapies. This...

Descripción completa

Detalles Bibliográficos
Autores principales:	Howell, Timothy A., Matza, Louis S., Jun, Monika P., Garcia, Jacob, Powers, Annette, Maloney, David G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9043043/ https://www.ncbi.nlm.nih.gov/pubmed/35129829 http://dx.doi.org/10.1007/s41669-021-00316-0

Ejemplares similares

Access to Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma
por: Snyder, Sophie, et al.
Publicado: (2021)

Complete spectrum of adverse events associated with chimeric antigen receptor (CAR)-T cell therapies
por: Yang, Chieh, et al.
Publicado: (2023)

Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma
por: Steiner, Raphael E., et al.
Publicado: (2021)

Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma
por: Strati, Paolo, et al.
Publicado: (2021)

Outcome Prediction in Patients With Large B-cell Lymphoma Undergoing Chimeric Antigen Receptor T-cell Therapy
por: Voltin, Conrad-Amadeus, et al.
Publicado: (2023)

Benefits of Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma
por: Zhou, Wenyujing, et al.
Publicado: (2022)

Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas
por: Chu, Fuliang, et al.
Publicado: (2023)

Hemophagocytic lymphohistiocytosis and disseminated intravascular coagulation are underestimated, but fatal adverse events in chimeric antigen receptor T-cell therapy
por: Song, Zhiqiang, et al.
Publicado: (2023)

Resource utilization for chimeric antigen receptor T cell therapy versus autologous hematopoietic cell transplantation in patients with B cell lymphoma
por: Ring, Alexander, et al.
Publicado: (2022)

Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL)
por: Tbakhi, Bushra, et al.
Publicado: (2022)

A Review of Chimeric Antigen Receptor T-Cell Therapy for Myeloma and Lymphoma
por: Atrash, Shebli, et al.
Publicado: (2021)

Case of Myocarditis After Chimeric Antigen Receptor T Cells With Intracardiac Lymphoma
por: Lee, Dae Hyun, et al.
Publicado: (2022)

B7-H3 Chimeric Antigen Receptor Redirected T Cells Target Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma
por: Zi, Zhenguo, et al.
Publicado: (2020)

Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma
por: Khurana, Arushi, et al.
Publicado: (2022)

Cardiac and inflammatory biomarker differences in adverse cardiac events after chimeric antigen receptor T-Cell therapy: an exploratory study
por: Lee, Dae Hyun, et al.
Publicado: (2023)

Chidamide and sintilimab combination in diffuse large B-cell lymphoma progressing after chimeric antigen receptor T therapy
por: Hao, Yuan-Yuan, et al.
Publicado: (2022)

Patient preferences and health state utilities associated with the treatment process of antiretroviral therapy for people living with HIV
por: Matza, Louis S., et al.
Publicado: (2022)

Health state utilities associated with hyperphagia: Data for use in cost‐utility models
por: Howell, Timothy A., et al.
Publicado: (2023)

Utilizing Chimeric Antigen Receptors to Direct Natural Killer Cell Activity
por: Hermanson, David L., et al.
Publicado: (2015)

Thrombotic Events Are Unusual Toxicities of Chimeric Antigen Receptor T-Cell Therapies
por: Schorr, Christopher, et al.
Publicado: (2023)

Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma
por: Lin, Richard J., et al.
Publicado: (2020)

Complete responses to odronextamab in two patients with diffuse large B‐cell lymphoma refractory to chimeric antigen receptor T‐cell therapy
por: Weinstock, Matt, et al.
Publicado: (2022)

CD19-Targeted Chimeric Antigen Receptor T-cell Therapy for Concomitant Diffuse Large B-cell Lymphoma and Multiple Myeloma
por: D'Ovidio, Tyler, et al.
Publicado: (2023)

Additional possibilities of chimeric antigen receptor T-cells in B-cell lymphoma: combination therapy
por: Yang, Yan, et al.
Publicado: (2020)

Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma
por: Yin, Zixun, et al.
Publicado: (2021)

Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel
por: Cartron, Guillaume, et al.
Publicado: (2022)

Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma
por: Zhou, Jin, et al.
Publicado: (2022)

Treatment-Related Adverse Events of Chimeric Antigen Receptor T-Cell (CAR T) in Clinical Trials: A Systematic Review and Meta-Analysis
por: Lei, Wen, et al.
Publicado: (2021)

The roles of T cell competition and stochastic extinction events in chimeric antigen receptor T cell therapy
por: Kimmel, Gregory J., et al.
Publicado: (2021)

Large-scale manufacturing of base-edited chimeric antigen receptor T cells
por: Woodruff, Rosie, et al.
Publicado: (2023)

Economic Evaluation of Chimeric Antigen Receptor T-Cell Therapy by Site of Care Among Patients With Relapsed or Refractory Large B-Cell Lymphoma
por: Lyman, Gary H., et al.
Publicado: (2020)

Liquid biopsy for disease monitoring after anti‐CD19 chimeric antigen receptor T cell in diffuse large B‐cell lymphoma
por: Maluquer, Clara, et al.
Publicado: (2020)

Cost-Effectiveness of Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma: No Impact of Site of Care
por: Cummings Joyner, Alice Kate, et al.
Publicado: (2022)

Chylothorax after chimeric antigen receptor T cell therapy for relapsed and refractory diffuse large B-cell lymphoma: A case report
por: Chen, Hsin-Hui, et al.
Publicado: (2023)

Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Large B-Cell Lymphoma (LBCL): A Single-Institution Experience
por: Trando, Aaron, et al.
Publicado: (2023)

Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer
por: Kandra, Prameela, et al.
Publicado: (2022)

Neurological Adverse Effects of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T-Cell Therapy
por: Khalid, Farhan, et al.
Publicado: (2023)

Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges
por: Makita, Shinichi, et al.
Publicado: (2019)

Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma
por: Ogasawara, Ken, et al.
Publicado: (2021)

Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma
por: Wu, Jiaying, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ck0bcg34ssutqdaph4ecj2leq2